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Abstract 
Background: The aim of this study was to test the hypothesis that vitamin D supplementation improves well‑being 
in patients with frequent respiratory tract infections (RTIs). We performed a post hoc analysis of a randomized, pla‑
cebo‑controlled and double‑blind study in which patients with frequent RTIs were randomized to placebo or vitamin 
D (4000 IE/day for 1 year, n = 124). At the last visit of the study, patients were asked to perform a general assessment 
of their well‑being during the study.
Results: The majority of patients, both placebo‑ and vitamin D treated, stated that they had felt ‘better’ during the 
study; 52 % in the placebo group and 70 % in the vitamin D group, relative risk 1.3 (95 % CI 1.0–1.8; p = 0.06, Fisher’s 
exact test). Statement of better well‑being was associated with an increase in 25‑hydroxyvitamin D (25‑OHD) levels 
(p < 0.001). In contrast, worse well‑being was associated with unchanged 25‑OHD levels. Notably, a 25‑OHD level 
above 100 nmol/L at the study end was associated with a higher chance of having a better well‑being (p < 0.01). 
Four patients on anti‑depressive treatment could terminate their antidepressant medication during the study. These 
patients had a significant increase in 25‑OHD levels from low levels at study‑start.
Conclusion: Vitamin D supplementation to patients with frequent RTIs might be beneficial, not only for infections, 
but also for their general well‑being. However, given the post hoc design of this study, these findings need to be 
confirmed in additional clinical trials before firm conclusions can be drawn.
Trial registration: http://www.clinicaltrials.gov (NCT01131858), registered March 22, 2010
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Background
Patients with primary immunodeficiency often have 
an impaired quality of life and a high risk for depres-
sive and anxiety disorders [1]. In a longitudinal study of 
92 patients with common variable immunodeficiency 
(CVID), an assessment of general health showed lower 
scores in these patients compared to patients with other 
chronic diseases. Approximately one-third of all patients 
in the cohort were at risk of anxiety/depression, and two-
thirds of the females [1].
Vitamin D is important for a healthy immune system 
and strengthens innate immunity by inducing synthesis 
of antimicrobial peptides [2]. In addition, vitamin D has 
broad anti-inflammatory effects on the adaptive immune 
system [3, 4]. Low levels of 25-hydroxyvitamin D (25-
OHD) are associated with an increased risk of respiratory 
tract infections (RTIs) [5]. Based on these findings, we 
conducted a randomized, placebo controlled and double 
blind study where patients with frequent RTIs were rand-
omized to placebo or vitamin D (4000 IE/day for 1 year). 
In this study (n  =  124) we could show that vitamin D 
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treated patients (n = 62) had significantly reduced infec-
tious symptoms, measured as “infectious score”, and a 
60  % reduction of antibiotic consumption compared to 
the placebo group (n = 62) [6].
Interestingly, vitamin D also seems to play a role in 
the central nervous system. Several reports have shown 
that low vitamin D levels is associated with increased 
risk of pain [7, 8] and that vitamin D supplementation 
can reduce depressive symptoms [9]. Thus, we hypothe-
sized that vitamin D supplementation could improve the 
overall well-being in patients with frequent RTIs. To test 
this hypothesis, we performed a post hoc analysis of our 
previously performed clinical trial [6]. The analysis was 
based on an assessment of well-being during the study 
year and this information was related to vitamin D levels 
and use of antidepressive medication.
Methods
Study cohort
We performed a post hoc analysis of data from our pre-
viously performed clinical trial [6]. This was a prospec-
tive, randomized and double-blind placebo-controlled 
study of vitamin D3 supplementation (4000  IU/day) in 
patients with an increased susceptibility to respiratory 
tract infections. The double-blind design implies that 
the randomization to placebo or vitamin D was blinded 
for both patients and the study-physicians and study-
nurses. Patient characteristics and inclusion criteria are 
described in details in the original article [6]. The current 
post hoc analyses is based on the per protocol cohort, 
which completed the study (n = 124). Of these, n = 62 
had placebo-treatment and 62 vitamin D-treatment; 
thirty-three were men and 91 women. The raw data is 
available from the corresponding author upon request.
In the original study we asked the patients at the end 
of the study (last visit) about their overall “well-being” 
during the study period. The overall health during the 
study year was assessed by a global assessment approach 
by asking a single question: “How do you rate your over-
all health during the study year compared with the year 
before inclusion”. The questionnaire contained the pre-
defined answers: 1 = better than before, 2 = worse than 
before, 3 = no change or 4 = other.
All statistical tests were performed using GraphPad 
Prism v. 6.00 and p  <  0.05 were considered statistically 
significant. The data including the whole cohort (Fig. 1) 
showed Gaussian distribution and thus mean values and 
SD are presented as well as 95 % confidence interval (CI). 
Student’s t-test was used to study the difference between 
before and after treatment. In the cohort of patients on 
anti-depressants (Fig. 2) the data lacked Gaussian distri-
bution and thus non-parametric Wilcoxon signed rank 
test was used.
Ethical statement
The study was approved by the regional Ethical Review 
Board at Karolinska Institutet, Stockholm, Sweden 
and by the Swedish Medical Products Agency. The 
study was registered at http://www.clinicaltrials.gov 
(NCT01131858) prior to inclusion of the first patient 
(registered March 22, 2010, approved May 26, 2010) and 
was conducted in accordance with the declaration of Hel-
sinki. Written informed consent was obtained from all 
participants prior to inclusion.
Results
Assessment of well‑being during study
The majority of patients, both placebo- and vitamin 
D treated, stated that they had felt ‘better’ during the 
study; 52  % in the placebo group and 70  % in the vita-
min D group, relative risk 1.3 (95 % CI 1.0–1.8; p = 0.06, 
Fisher’s exact test). Among the patients that stated a bet-
ter well-being during the study (n = 72) there was a sig-
nificant increase in 25-hydroxyvitamin D levels (25-OHD 
levels) during the study, mean levels increased from 
50 (SD ±22) to 87 (SD ±48) nmol/L (p  <  0.001); 95  % 
CI before 45–55; after 76–99  nmol/L. Among patients 
who reported no difference in well-being (n = 32) there 
was also an increase in 25-OHD levels, but to a lesser 
extent; mean levels increased from 46 (SD ±22) to 68 
(SD ±44) nmol/L (p < 0.05); 95 % CI before 38–54; after 
52–84 nmol/L. Among patients who stated a worse well-
being during the study (n = 14) there was no significant 
increase in 25-OHD levels, mean levels increased from 
51 (SD ±24) to 68 (SD ±33) nmol/L (p = 0.14); 95 % CI 
before 37–54; after 49–87  nmol/L. A level of 25-OHD 
above 100 nmol/L seemed to be associated with a higher 
chance of experiencing a better well-being (p < 0.01, χ2 
test, Fig.  1). Levels above 75  nmol/L were not signifi-
cantly associated with a better well-being (p = 0.16).
Use of antidepressive drugs in the study
Data about anti-depressive medications were recorded in 
the original study [6]. At the study start 22 patients were 
taking antidepressants, 2 men and 20 women. The mean 
25-OHD level was 56 nmol/L among these patients (95 % 
CI 45–68 nmol/L) which was mainly the same as in the 
whole cohort; mean 49 nmol/L (95 % CI 45–53 nmol/L). 
At the end of the study, 10 of these 22 patients stated 
a better well-being, 6 answered no difference and 6 
reported a worse well-being (Fig. 2). The patients that had 
a better well-being during the study had a mean signifi-
cant increase in 25-OHD levels (p < 0.001), whereas the 
other patients had no increase (Fig. 2). Interestingly, four 
subjects could terminate their anti-depressive treatment 
during the study and all these individuals reported a bet-
ter well-being (marked with red lines in Fig. 2). All these 
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subjects had a significant increase in 25OHD-levels, from 
low levels at study-start, 19–57 to 74–150 nmol/L at the 
study-end.
Discussion
We and others have shown that vitamin D supplemen-
tation may be beneficial for preventing RTIs (reviewed 
in [10]). Here, we show that a significant increase in 
Fig. 1 Well‑being in patients with immunodeficiency disorders before and after 1 year of supplementation with vitamin D. In patients with a better 
well‑being during the study (n = 72) there was an average increase in 25‑hydroxyvitamin D levels (25‑OHvitD) (p < 0.001, Student’s t‑test). Likewise, 
in patients with no difference in well being (n = 32) there was an average increase, but less pronounced (p < 0.05, Student’s t‑test). In patients stat‑
ing a worse well‑being (n = 14) there was no significant increase (ns not significant)
Fig. 2 Well‑being in patients with immunodeficiency disorders taking antidepressants, before and after a 1 year vitamin D study. In patients with 
a better well‑being during the study (n = 10) there was an average increase in 25‑hydroxyvitamin D (25‑OHvitD) levels (p < 0.001, Wilcoxon signed 
rank test). Four patients could terminate their antidepressant therapy during the study (red lines). In patients stating no difference (n = 6) or worse 
well‑being (n = 6) there was no change in average 25‑OHvitD levels (p = not significant)
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25-OHD levels is associated with a better well-being 
in patients with frequent RTIs. Based on these data, 
100 nmol/L appears to be a tentative threshold for a ben-
eficial effect on well-being in these patients. Interestingly, 
when 100 nmol/L was tested as a threshold for infectious 
score, a similar beneficial effect could not be observed 
(data not shown). Thus, the reporting of a better well-
being could not solely be explained by a reduced infec-
tious burden, suggesting that other mechanism could 
have contributed to the result.
In fact, vitamin D supplementation may be beneficial in 
the treatment of depression but the effects seems to be 
moderate [11] and the results are still inconclusive [9]. In 
addition, several studies have shown that vitamin D sup-
plementation may reduce chronic pain [7, 8, 11, 12]. In a 
randomized, placebo-controlled trial in elderly (n = 120) 
vitamin D in a single megadose increased quality of life 
and reduced pain [13]. To our knowledge, the present 
study is the first where vitamin D status in patients with 
frequent RTIs is correlated to an overall assessment of 
well-being. An interesting notion is that 52 % of the pla-
cebo-treated patients stated a ‘better’ well-being during 
the study, indicating an important beneficial placebo-
effect of “any” treatment (vitamin D or placebo). Usually, 
the placebo effect is estimated to 30 % of the effect of a 
treatment but this figure might be underestimated [14].
The present study is carried out in Sweden with large 
seasonal variability of 25-OHD levels in the population 
between summer and winter due to limited sunlight 
exposure during the winter time [7]. The lowest levels of 
25-OHD levels in a Scandinavian population are in Feb-
ruary–March [15]. In Sweden and Finland depressions 
are most common in spring-time and the suicide peak is 
in May [16]. Although many factors might contribute to 
this fact it could be speculated that low 25-OHD levels 
during early spring-time might contribute to impaired 
well-being in the population during spring.
It could not be excluded that the results presented here 
might at least in part be explained by confounding fac-
tors. Fewer respiratory tract infections in patients with 
a large increase in 25-OHD levels might have contrib-
uted to the results of better well-being. Moreover, suffi-
cient 25-OHD levels improves general health [17], thus 
improved well-being might be explained by better physi-
cal condition. Furthermore, a recent article suggested 
that UVB-light has strong analgesic effects by induction 
of endogenous opioid-like substances (endorphins) in 
the skin [18]. Thus, vitamin D levels could only serve as 
a maker for UVB-exposition and the association between 
vitamin D levels and well-being could be explained by 
exposure to the sun and endogenous synthesis of endor-
phins. However, our study has an interventional design 
and thus the most reasonable cause of the observed 
increase in 25-OHD levels is vitamin D supplementation 
and not increased UVB-exposition, making this explana-
tion less likely.
One limitation of the present study was that the trial 
was not designed to study well-being and the data pre-
sented here is a post hoc analysis. We did not use a vali-
dated questionnaire for evaluation of “quality of life” or 
depression, such as GHQ-12, SF-36 [1] or MADRS [19]. 
Instead, the overall health during the study year was 
assessed by a global assessment approach by asking a 
single question. It should also be noted that the current 
analysis is performed per protocol and not as intention to 
treat. However, we believe that the per protocol analysis 
represent the data in a valid manner, since there was an 
equal amount of patients excluded from each arm. The 
reasons for exclusion were mainly due to lack of compli-
ance to the protocol, i.e. not taking the drug or not fill-
ing out the diary. Importantly, there was no tendency that 
any reason for exclusion was associated with a specific 
allocation (vitamin D/placebo), thus minimizing the risk 
of bias in a per protocol analysis. In addition, the allo-
cation between vitamin D and placebo does not play a 
major role in this post hoc analysis, since the most inter-
esting result is based on the measured 25-OHD levels 
and the relation to well-being and not based on allocation 
to vitamin D or placebo treatment.
Notably, in the original study vitamin D treatment 
was well-tolerated and no severe adverse events were 
reported in the study. Indeed, there were more adverse 
events reported among the placebo-treated patients than 
in the vitamin D treated patients, indicating that this is a 
safe treatment [6].
Conclusion
Vitamin D supplementation could be a safe, cheap and 
accessible option to improve both physical health and 
well-being in patients with frequent RTIs. However, given 
the post hoc design of this small hypothesis-generating 
study, these findings need to be confirmed in additional 
clinical trials before firm conclusions can be drawn.
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